Therapeutic Asset Ratings

146 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cald Hr-D Globoid Cell Leukodystrophy	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Glycoprotein Metabolic Disorders	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation)	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Hunter Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Hurler Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Infantile Refsum Disease	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Inherited Metabolic Disorders	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Maroteaux Lamy Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Metachromatic Leukodystrophy	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Mitochondrial Neurogastrointestingal Encephalopathy	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Mucopolysaccharidosis Disorders	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Multifunctional Enzyme Deficiency	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Neonatal Adrenoleukodystrophy	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Niemann-Pick B	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Niemann-Pick C Subtype 2	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Peroxisomal Disorders	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Recessive Leukodystrophies	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Severe Osteopetrosis	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Sly Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Sphingolipidoses	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Sphingomyelin Deficiency	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cald Hr-D Zellweger Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Polymer-Lipid Nanoparticle-Mediated Delivery Of Cd19/Cd20 Dual-Targeting Invivocar1920 Mrna For Car-T Cell Immunotherapy B-cell Lymphoma Refractory	Daihong Liu	P2	CCC (53)
Tas-102 Advanced Lymphoma	National Cancer Institute (NCI)	P2	CCC (53)
Tas-102 Advanced Malignant Solid Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)

Showing 51 to 75 of 146 assets

PreviousPage 3 of 6Next